Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B

被引:503
作者
Yuen, Man-Fung [1 ]
Tanaka, Yasuhito [2 ]
Fong, Daniel Yee-Tak [3 ]
Fung, James [1 ]
Wong, Danny Ka-Ho [1 ]
Yuen, John Chi-Hang [1 ]
But, David Ylu-Kuen [1 ]
Chan, Annie On-On [1 ]
Wong, Benjamin Chun-Yu [1 ]
Mjzokami, Masashi [2 ]
Lai, Ching-Lung [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Nagoya City Univ, Grad Sch Med Sci, Dept Clin Mol Informat Med, Nagoya, Aichi, Japan
[3] Univ Hong Kong, Queen Mary Hosp, Dept Nursing Studies, Hong Kong, Hong Kong, Peoples R China
关键词
Chronic hepatitis B; Hepatocellular carcinoma; Risk factor; Prediction; BASAL CORE PROMOTER; VIRUS GENOTYPE-B; E-ANTIGEN; PRECORE MUTATIONS; LIVER-DISEASE; VIRAL LOAD; DNA LEVELS; HONG-KONG; INFECTION; CARRIERS;
D O I
10.1016/j.jhep.2008.07.023
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: To determine whether gender, age, hepatitis B virus genotype, core promoter and precore mutations, HBeAg/anti-HBe status, HBV DNA, ALT levels and cirrhosis on presentation were independent risk factors and derive a novel risk score for the development of HCC. Methods: CHB patients (820) were followed up (mean duration 76.8 months) for the occurrence of HCC. Results: The 5- and 10-year prevalence of HCC were 4.4% and 6.3%, respectively. Cox regression analysis showed that male gender (p = 0.025, RR 2.98), increasing age (p < 0.001, RR 1.07), higher HBV DNA levels (p = 0.02, RR 1.28), core promoter mutations (p = 0.007, RR 3.66), and presence of cirrhosis (p < 0.001, RR 7.31) were independent risks for the development of HCC. A risk score was derived and validated with sensitivity > 84% and specificity > 76% to predict the 5- and 10-year risks for the development of HCC. The AUC for the 5- and 10-year prediction were 0.88 and 0.89, respectively. Conclusions:The risk score, based on age, gender, HBV DNA levels, core promoter mutations and cirrhosis, can estimate the chance of development of HCC in 5 and 10 years after presentation. It can be used to identify high-risk CHB patients for treatment and screening of HCC. (C) 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 88
页数:9
相关论文
共 31 条
[1]  
[Anonymous], ELEMENTS STAT LEARNI
[2]   High prevalence of 1762T 1764A mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers [J].
Baptista, M ;
Kramvis, A ;
Kew, MC .
HEPATOLOGY, 1999, 29 (03) :946-953
[3]  
BEASLEY RP, 1981, LANCET, V2, P1129
[4]   Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma [J].
Chan, HLY ;
Hui, AY ;
Wong, ML ;
Tse, AML ;
Hung, LCT ;
Wong, VWS ;
Sung, JJY .
GUT, 2004, 53 (10) :1494-1498
[5]   Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India [J].
Chauhan, R ;
Kazim, SN ;
Bhattacharjee, J ;
Sakhuja, P ;
Sarin, SK .
JOURNAL OF MEDICAL VIROLOGY, 2006, 78 (08) :1047-1054
[6]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[7]   Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma [J].
Chou, Y-C ;
Yu, M-W ;
Wu, C-F ;
Yang, S-Y ;
Lin, C-L ;
Liu, C-J ;
Shih, W-L ;
Chen, P-J ;
Liaw, Y-F ;
Chen, C-J .
GUT, 2008, 57 (01) :91-97
[8]   Histological outcome during long-term lamivudine therapy [J].
Dienstag, JL ;
Goldin, RD ;
Heathcote, EJ ;
Hann, HWL ;
Woessner, M ;
Stephenson, SL ;
Gardner, S ;
Gray, DF ;
Schiff, ER .
GASTROENTEROLOGY, 2003, 124 (01) :105-117
[9]  
Fujie H, 2001, GASTROENTEROLOGY, V120, P1564, DOI 10.1053/gast.2001.24501
[10]   Time-dependent ROC curves for censored survival data and a diagnostic marker [J].
Heagerty, PJ ;
Lumley, T ;
Pepe, MS .
BIOMETRICS, 2000, 56 (02) :337-344